Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

J&J drops Achillion HCV deal

September 15, 2017 9:09 PM UTC

Johnson & Johnson (NYSE:JNJ) terminated a 2015 deal with Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) to develop and commercialize HCV therapies, including triplet therapy JNJ-4178. J&J said it decided to discontinue development of JNJ-4178 “in light of the increasing availability of a number of highly effective therapies addressing the medical need in hepatitis C.”

J&J says it will shift its hepatitis R&D efforts to discovering a functional cure for HBV (see BioCentury, Aug. 11)...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article